Status:
RECRUITING
Insulin Regulation of Lipolysis and Lipolysis Proteins
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Obesity
Eligibility:
All Genders
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discove...
Detailed Description
1. The investigators will determine whether impaired insulin-induced suppression of lipolysis (as measured by IC50) is related to the above mentioned lipolysis proteins in groups of volunteers known t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and Women between the ages of 18 and 55.
- Women will be premenopausal
- Non obese adults BMI between 18-25
- Obese BMI 30-38
- Exclusion Criteria, Pioglitazone package insert of contraindications for use:
- Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
- Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.
Exclusion
Key Trial Info
Start Date :
November 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03866408
Start Date
November 12 2018
End Date
December 31 2025
Last Update
January 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905